Do non-opioid pain medications offer adequate pain control compared to opioids, following rhinoplasty?
Early and Sustained Improvements in Sense of Smell with Tezepelumab Treatment in Patients with CRSwNP (WAYPOINT)
In WAYPOINT, tezepelumab produced early and sustained improvements in patient-reported and objective smell outcomes compared with placebo, and markedly reduced the proportion of patients with UPSIT-defined anosmia.
Asthma Outcomes Following Early Versus Delayed Sinus Surgery in CRSwNP
Early ESS was associated with lower rates of moderate and severe persistent asthma, fewer asthma exacerbations, and reduced utilization of systemic steroids, LABAs, and biologic therapies compared with delayed surgery.
Patient and Procedural Predictors of Early Recovery Quality after Endoscopic Endonasal Surgery
Which patient and procedural factors influence early post-operative recovery quality and PACU outcomes after EES?
The Impact of Chronic Particulate Matter Exposure on Quality-of-Life Outcomes after ESS
Does chronic pre-operative exposure to fine particulate matter (PM2.5) affect QoL outcomes after ESS in patients with CRS?
Efficacy of Local Bupivacaine Injection for Post-Operative Pain in Endoscopic Sinus Surgery
Does general anesthesia in combination with local bupivacaine injection at the SPG and anterior ethmoid nerve reduce post-operative pain after
ESS?
Healthcare Resource Utilization and Cost After TCRF Treatment of Nasal Airway Obstruction: A Real-World Longitudinal Claims Analysis
Does TCRF treatment for NVC-related NAO reduce healthcare utilization and overall costs compared with medical management?
Short-Term Efficacy of Biologics in Recalcitrant AFRS: A Systematic Review and Meta-Analysis
Do biologic therapies improve symptoms, endoscopic findings, and inflammatory markers in patients with recalcitrant allergic fungal rhinosinusitis?
Randomized Trials Comparing Inferior Turbinoplasty Techniques for Nasal Obstruction
Which inferior turbinoplasty techniques provide the most durable improvement in nasal obstruction symptoms over long-term follow-up?
Dupilumab Monthly Dose De-Escalation Maintains Efficacy in CRSwNP
Does extending dupilumab dosing from every two weeks to every four weeks maintain clinical efficacy in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP)?
- 1
- 2
- 3
- …
- 18
- Next Page »